secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001193125-23-159898
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences reaffirms FY23 revenue guidance; WPS proposes limiting MIGS coverage for OMNI
--------------------------------------------------------------------------------

- Reaffirmed FY2023 revenue guidance of $89M-$94M (25%-32% growth YoY); quarterly adjusted opex ~$30.5M.
- WPS (Medicare contractor) proposed LCD classifying non-implantable MIGS as investigational; would make OMNI non-covered in 6 states.
- WPS-served states (KS, NE, MO, IA, IN, MI) accounted for ~8% of Surgical Glaucoma revenue in 2022.
- Company strongly disagrees, plans to present clinical evidence at WPS meeting June 14 and comment period through July 15.
- Precedent: Palmetto GBA withdrew similar 2020 LCD after ophthalmic community pushback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000119312523159898/0001193125-23-159898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000119312523159898/d515447d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-159898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer